Clinical Trial

A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC

Name: A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC — clinical trial record (NCT07376629)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Enrolling by Invitation Phase 2

View on ClinicalTrials.gov →

Summary

This trial is a Phase II study. The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of HB0025 administered with chemotherapy in participants with locally advanced or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic breast cancer (mBC).

Trial Details

NCT Number	NCT07376629
Lead Sponsor	Huabo Biopharm Co., Ltd.
Conditions	TNBC
Enrollment	60 participants
Start Date	2025-08-14
Primary Completion	2027-01-15 (estimated)
Study Completion	2027-01-15 (estimated)
Updated on ClinicalTrials.gov	2026-01-29